All In MedTech

Device Trial Radar · NCT07938567

Preeclampsia Screening Trial to Improve Outcomes

Preeclampsia Screening Trial to Improve Outcomes: A Pre and Post Cohort Trial to Evaluate the Use of sFlt-1/PlGF Ratio in Women With Hypertensive Disorders of Pregnancy

Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

1,000

Planned (sponsor's estimate)

Start

Dec 2026

Primary completion

Jun 2028

Study completion Jun 2028

Sponsor

Lead sponsor
Emory UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Nov 16, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Diagnostic
FDA-regulated device
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The Pre-eclampsia Screening Trial to Improve Outcomes (PRESTO) research study aims to assess how clinicians use a blood test to guide care decisions in determining preeclampsia risk, with the overall aim of improving outcomes for both pregnant persons and their babies. The study will evaluate whether a blood test can help doctors better identify pregnant patients with hypertensive disorders of pregnancy who are at risk of developing severe pre-eclampsia, which is a serious pregnancy condition that can affect organs such as the liver and kidneys and often leads to preterm delivery. The lab test measures two naturally occurring proteins in the blood that help estimate short-term risk for worsening disease. The goal is to determine whether providing this lab test result to clinicians can improve outcomes including safely prolong pregnancy, reduce unnecessary preterm deliveries, improve newborn outcomes, and optimize hospital care, without increasing complications for pregnant women or causing excess risks to the baby.

Conditions

  • Pregnancy Related
  • Hypertensive Disorder of Pregnancy (HDP)

Interventions

  • Kryptor sFlt-1/PlGF assays on serum/plasmaDevice

    Serum sFlt-1/PlGF biomarker, authorized by the U.S. Food and Drug Administration for use in pregnant patients with hypertensive disorders of pregnancy from 23+0 through 33+6 weeks of gestation.

  • TreatmentOther

    sFlt-1/PlGF measurements will be available to clinicians in real time and may be incorporated into clinical management according to the FDA-approved algorithm

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pregnancy latencyTime frame: At delivery (up to 40 weeks of gestation)
  2. Participants with maternal adverse outcomesTime frame: From enrollment until post-natal discharge (on average 10 days post-delivery)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Emory Decatur Hospital

    Decatur, Georgia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.